Adverum Biotechnologies Inc is at the forefront of gene therapy, focusing on developing treatments for ocular and rare diseases. Their main project, ixoberogene soroparvovec, aims to address chronic retinal conditions like wet age-related macular degeneration and diabetic macular edema through a single injection. They're also working on a therapy for blue cone monochromacy. Originating in 2006 and based in Redwood City, California, Adverum has evolved through strategic partnerships with notable institutions and companies, emphasizing its commitment to innovative healthcare solutions.